To evaluate outcome and complications of knee arthrodesis with a modular prosthetic system (MUTARS(r) Implantcast), as primary and revision implants in musculoskeletal oncology. Between 1975 and 2009, 24 prostheses were used for knee arthrodesis. Nineteen in oncologic cases: 6 osteosarcomas, chondrosarcoma, synovial sarcoma and metastatic carcinoma 3 each, 2 pigmented villonodular synovitis (PVNS), malignant fibrous hystiocitoma and giant cell tumour 1 each. Patients were grouped into: A) primary implants, B) revision implants. Group A included 9 patients: 8 arthrodeses after extra-articular resection with major soft tissue removal, 1 after primary resection following multiple excisions of locally recurrent PVNS. Group B included 15 patients: 12 arthrodeses for infection (5 infected TKAs, 7 infected megaprostheses), 2 for failures of temporary arthodesis with Kuntscher nail and cement, 1 for recurrent chondrosarcoma in previous arthrodesis.Aim
Method
We retrospectively studied 14 patients with proximal and diaphyseal tumours and disappearing bone (Gorham’s) disease of the humerus treated with wide resection and reconstruction using an allograft-resurfacing composite (ARC). There were ten women and four men, with a mean age of 35 years (8 to 69). At a mean follow-up of 25 months (10 to 89), two patients had a fracture of the allograft. In one of these it was revised with a similar ARC and in the other with an intercalary prosthesis. A further patient had an infection and a fracture of the allograft that was revised with a megaprosthesis. In all patients with an ARC, healing of the ARC-host bone interface was observed. One patient had failure of the locking mechanism of the total elbow replacement. The mean post-operative Musculoskeletal Tumor Society score for the upper extremity was 77% (46.7% to 86.7%), which represents good and excellent results; one patient had a poor result (46.7%). In the short term ARC effectively relieves pain and restores shoulder function in patients with wide resection of the proximal humerus. Fracture and infection remain significant complications.
Objective of this study was to analyse results of two stage revisions in infected megaprostheses in lower limb.
Infection occurred in 80 cases (7.7%) at mean time of 4 yrs (min 1 month, max 19 yrs) in 18 KMFTR®, 47 HMRS®, 5 HMRS® Rotating Hinge, 10 GMRS®. Sites: 51 distal femurs, 21 proximal tibias, 6 proximal femurs, 1 total femur and 1 extrarticular knee resection. Most frequent bacteria causing infection were: Staphilococcus Epidermidis (39 cases), Staphilococcus Aureus (17) and Pseudomonas Aeruginosa (5). Infection occurred postoperatively within 4 weeks in 9 cases, early (within 6 months) in 12 cases, late (after 6 months) in 59 cases. Usual surgical treatment was “two stage” (removal of implant, one or more cement spacers with antibiotics, new implant), with antibiotics according with coltures. One stage treatment was used for immediate postoperative infections, only since 1998. Functional results after treatment of infection were assessed using the MSTS system.
In 3 cases an amputation was primarily performed, to proceed with chemotherapy. Revisions for infection were successful in 63 pts (79%), while 17 pts were amputated (21%). Functional results evaluated in 53 revised cases were good or excellent in 43 (81.1%).
Patients included 44 females and 38 males, ranging in age from 14 to 74 years. Mean follow-up was 9.5 years (min. 3, max. 27). Histopathological findings included chordomas in 55 cases and giant cell tumor (GCT) in 27. Most pts. had iv antibiotic therapy with amikacin and teicoplanin. Surgery of chordoma was resection, surgery of GCT was intralesional excision. In 6 sacral resections a miocutaneous transabdominal flap of rectus abdominis was used for posterior closure.
Mean surgical time was 14 hours for resections and 6 hours for excisions. No significant difference was found comparing deep wound infections with levels of resection (15/33 resections proximal to S3-45% and 8/19 resections below or at S3-42%), previous intralesional surgery elsewhere (4/9 patients previous treated elsewhere-44% and 19/46 primarily treated patients-41%) and age at surgery.
S. Epidermidis and S. Aureo were the most frequent bacteria causing infection (45%). Two stage treatment of infection was chosen: removal of the implant and temporary substitution with cement spacer with antibiotics (usually vancomycin) until infection healed. But a new prostheses was actually implanted in 3 cases only (at mean time of 5.7 mos), while in 17 the spacer was never removed by patients choice due to the acceptable result with the spacer. Systemic antibiotics were associated according to cultural results. Infection healed in all patients.
Purpose was to evaluate the incidence of complication in lower limb reconstructions with modular prostheses comparing cemented versus uncemented stems in two different orthopedic tumor Centers.
From 2002 and 2007, 238 modular prostheses of same design with a rotating hinge knee, were implanted in the lower limb as primary reconstruction in these two Centers. In 130 cases the prosthesis was implanted with cemented stems and in 108 cases with uncemented stems. Sites included: 120 distal femur, 61 proximal femur, 46 proximal tibia, 10 total femur and in 1 case both distal femur and proximal tibia. Histologic diagnoses included: 89 osteosarcoma, 13 Ewing sarcoma, 21 chondrosarcoma, 19 sarcoma, 55 metastasis, 17 TGC, 7 MFH, 11 other diagnoses and 6 non oncologic cases. Major prostheses-related complications were analysed and functional results according to Muscolo Skeletal Tumor Society system, at a mean follow up of 2.03 yrs. Also a statistical evaluation with Kaplan Meier curves, a comparative statistical analysis with Wilcoxon test and multivariate Cox regression analysis were performed.
Infections occurred at mean time of 1.3 yrs, sites included: 9 distal femurs, 4 proximal femurs, 5 proximal tibias, 2 total femurs. Aseptic loosening occurred at mean time of 2.3 yrs, sites included: 3 proximal tibias, 2 distal femurs, 2 proximal femurs. Rate of aseptic loosening was higher for cemented stems 5/130 (3.85%) vs uncemented 2/108 (1.85%). This difference is not statistically significant. Infection rate was 10% (13/130) for cemented stems and 6.5% (7/108) for uncemented stems. This difference is statistically significant at comparison of survival curves logrank test. Average MSTS function score was 83.5%. Multivariate Cox regression analysis showed that the significant factor favourable reluted with lower incidence of complications was the use of uncemented stems.
In the upper limb, in 20 patients (5.8%) a revision for deep infection was required. Two infections were postoperative, 7 early and 11 late. S. Epidermidis and S. Aureo were the most frequent bacteria causing infection (45%). “Two stage” treatment of infection was performed, but a new prostheses was implanted in 3 cases. In 17 the spacer was never removed. In the sacrum, no deep infections were observed after intralesional excision for giant cell tumors. In 23/52 resections (44%) for chordoma (3 pts. died postoperatively and were excluded), infection occurred: in 16 patients postoperatively, in 7 within 6 months. Bacteria causing infection were mostly gram negative: in 74% of cases infection was multiagent. Surgical treatment consisted in one or more surgical debridements with antibiotics therapy according to coltures: infection healed in all cases.
Short intense electrical pulses transiently increase the permeability of the cell membrane, an effect known as electroporation. This can be combined with antiblastic drugs for ablation of tumours of the skin and subcutaneous tissue. The aim of this study was to test the efficacy of electroporation when applied to bone and to understand whether the presence of mineralised trabeculae would affect the capability of the electric field to porate the membrane of bone cells. Different levels of electrical field were applied to the femoral bone of rabbits. The field distribution and modelling were simulated by computer. Specimens of bone from treated and control rabbits were obtained for histology, histomorphometry and biomechanical testing. After seven days, the area of ablation had increased in line with the number of pulses and/or with the amplitude of the electrical field applied. The osteogenic activity in the ablated area had recovered by 30 days. Biomechanical testing showed structural integrity of the bone at both times. Electroporation using the appropriate combination of voltage and pulses induced ablation of bone cells without affecting the recovery of osteogenic activity. It can be an effective treatment in bone and when used in combination with drugs, an option for the treatment of metastases.
Purpose of this study was to analyse the different techniques of prosthetic reconstruction of the humerus (also in association with bone grafts) after resection of primary tumors, discussing indications and evaluating implant survival.
Histologically 24 were benign tumors and 253 primary malignant tumors. All patients were periodically followed in the clinic, imaging studies and histology were reviewed and special attention given to prostheses-related complications and implant survival. Univariate analysis through actuarial Kaplan Meier curves was used in evaluating implant survival to major complications. Functional results were assessed using the MSTS system.
Major complications of the implants included 19 cases of deep infection (6.8%), 8 aseptic loosenings (2.9%), 4 breakages (1.4%) causing failure of the implants requiring revisions. Further complications were observed in revised cases. Actuarial curve of implant survival to major complications showed over 80% at 10 years and over 70% at 20 years. Functional results according to the MSTS system were good or excellent (over 50%) in more than 90% of the patients, with an average score of 79%.
Most common mistakes adversely affecting treatment were wrong skin incisions and/or surgical approach, amount and quality of the biopsy sample, infection.
Purpose of this study is to analyze the results of a modular reconstructive tumor prosthesis for the lower limb (GMRS®) with a comparative statistical analysis of primary and secondary implants.
Gorham-Stout disease (GSD) is rare, characterized by proliferation of vascular channels resulting in progressive distruction of bone. In the Rizzoli files we found 15 cases of GSD from 1968 to 2008. Two were excluded for insufficient documentation. For 13 cases clinical data, imaging and histology were analysed. Histopathologic features included benign vascular proliferation, vascular pattern of osteolytic angioma, fibro-connective tissue component and bony destruction. A final diagnosis was established based on clinical, radiological and histopathologic features. Imaging included X-rays in 11 cases and CT or MRI in 5. All lesions were lytic, with associated sclerosis in two cases. There was one lesion only in 4 cases, multiple lesions in the same bone in 1 and multiple bones involved in 6. Primary sites were proximal femur in 7 cases, pelvis in 2, hip and knee, calcaneus, humerus and cervical spine in 1 case each. Two patients had no treatment, 2 conservative treatment (cast or brace), 5 surgery, 6 medical treatment (byphosphonates, calcitonin, zoledronic acid, interferon, steroids), 1 radiotherapy, 2 selective arterial embolization. Surgery consisted of internal fixation of pathologic fractures in 4 patients and reconstruction of the entire humerus with a double composite allograft in 1. Treatment was surgery only in 2 patients, medical treatment in 4 (1 also embolization), surgery and medical treatment in 2 (1 also embolization), radiotherapy only in 1, conservative treatment in 2. Four patients were lost at follow up. Mean follow up was 17 ys.(min 2, max 30) in 9 patients: 2 dead, 3 healed, 3 with stable disease, 1 alive with disease at 24 ys. No conclusive treatment recommendations are possible; surgery is indicated in pathologic fractures or reconstruction of massively destroyed bones, medical treatment and selective embolization are helpful. In literature prosthetic reconstruction is preferred due to the risk of allografts resorption.
Solitary fibrous tumour (SFT) is a relatively uncommon mesenchymal neoplasm that most frequently arises in the pleura, but is also known to affect extrathoracic sites. About 15 % of SFT’s behave in an aggressive way, giving rise to local recurrence and/or distant metastasis. However, the behaviour of SFT remains unpredictable and due to the rarity of this tumour, it is difficult to define prognostic factors. The purpose of this study was to describe our experience with SFT, trying to define the pathologic features of this rare entity and better understand its clinical behaviour. We performed a clinicopathologic review of all cases treated for a SFT at the Istituto Ortopedico Rizzoli in Bologna, between 1996 and 2008. We included 24 patients, nine males and fifteen females, ranging in age from 22 to 82 years (median 43.5 years). The anatomical sites involved were: the thigh (12 cases), shoulder region (four cases), gluteus (three cases), foot (two cases), extrapleural thoracic wall (two cases), and the lower leg (one case). The tumour was >
5 cm in 15 cases, ranging in diameter from 2.5 cm to 18 cm (median 7.5 cm). Pain and swelling were the most frequently reported symptoms at presentation, with a mean duration of symptoms of 10 months. All patients were treated by excisional surgery (wide margins in 11, marginal margins in 13). Three patients had undergone pre-operative radiotherapy (44Gy) and one of these had also adjuvant radiotherapy after marginal excision of the tumour. Six tumours showed at least one atypical histologic feature (moderate to marked cytological atypia, extensive tumor necrosis, ≥ four mitoses per ten high-power fields, or infiltrative margins). On immunohistochemistry, 21 cases were positive for CD-34, 10 for CD-99, 17 for vimentin, three for CD-31, four for actin and one for S-100. Subsequent follow-up (average 33 months, range 5 to 112 months) revealed tumour relapse in only one case: a bone metastasis after 36 months of follow-up. The initial lesion was considered a large, deep, malignant SFT of the thigh, treated with wide surgical excision. In the current review, including 24 extrathoracic solitary fibrous tumours, all lesions but one had a benign course. Nevertheless, this entity has a potential to recur or metastasize, and therefore careful long-term follow-up is necessary for all patients, even after wide excisional surgery. Although specific prognostic factors are yet to be defined, a high degree of suspicion for malignant behaviour is warranted for those cases in which atypical histologic features are present, particularly in the context of a deep tumor >
5cm in diameter.
Between 1983 and 2006 at Rizzoli 669 knee modular uncemented prostheses were implanted after resection of the distal femur, total femur or proximal tibia. These prostheses include 126 KMFTR prostheses and 543 second generation HMRS prostheses. Patients were followed periodically in the clinic. Data was obtained from clinical charts and imaging studies with special attention to major complications requiring revision surgery. Revision for polyethylene wear was considered a minor complication, since it did not imply failure of the implant. Functional results were assessed according to the MSTS system. Since data could be misleading due to deaths in an oncologic population (although 2/3 of patients were cured or long survivors), to censore the implant unrelated events Kaplan-Meyer curves of implant survival were studied. In 126 KMFTR group infection rated 13.5%, stem breakage 13%, aseptic loosening 9.5%; change of polyethylene rated 44%. In 543 HMRS prostheses infection rated 8.6%, stem breakage 3%, aseptic loosening 4.8%; revision for polyethylene wear rated 9.6%. Techniques of revisions and their outcome analysed showed about 2/3 of good results, but increased risk of further complications in revised implants. Functional results (MSTS system) were good or excellent in 80% of KMFTR prostheses and in 90% of HMRS. Decrease of major complications in newer prosthetic design was statistically significant and possibly due to newer materials and modified stem design. Polyethylene wear also decreased significantly. Function was satisfactory in most patients without complications for both groups. Revision surgery is technically demanding and appropriate timing of revision is crucial, since early treatment can improve final outcome.
From October 2003 to September 2007 at Rizzoli 161 GMRS® prostheses were implanted after resections of the lower limb. This is a modular system with a knee rotating hinge mechanism, cemented and uncemented stems, in titanium and chromium-cobalt-molybdenum, curved and straight-fluted, with or without hydroxyapatite coating. Adaptors are available to revise HMRS® prostheses with hybrid implants. This study includes 88 males and 73 females ranging in age from 9 to 80 years. Sites of reconstruction were 109 distal femurs, 19 proximal femurs, 1 total femur and 32 proximal tibias. There were 149 oncologic and 12 non oncologic diagnoses, including 96 primary reconstructions and 65 revisions for failures of previous reconstructions. Analysis of imaging and complications was performed and function assessed according to MSTS system. Kaplan-Meier curves were used to statistically evaluate implant survival. At a mean follow up of 2.5 yrs. 106 patients are continuously NED, 31 NED after treatment of relapse, 7 AWD, 5 DWD. There were 10 major complications: 8 infections (4.7%) (5 in primary and 3 in secondary implants) and 2 aseptic loosenings (1.2%) (1 each). There were 9 minor complications requiring minor revisions. Comparative statistical analysis of implant survival showed no statistically significant difference between primary and secondary implants. Functional results were good or excellent in 95% of patients, without any poor. Middle term results are promising with no breakages of implant components. Besides oncological cases, there are selected indications in non oncological settings, such as revisions of prosthetic or allografts failures. While a higher complication rate was expected in secondary implants, statistical analysis shows similar survival.
Forty-six hemangioendotheliomas (HE) of bone treated at Rizzoli from 1985 to 2004 were studied with minimum follow up of 4 years: 19 females and 27 males, mean age 37 years, mean follow-up 9 years, 35 cases unifocal at diagnosis (10 spine – 1 with lung metastasis also- 11 lower limb, 8 upper limb, 6 pelvis) and 11 with multifocal involvement. In 10 patients intralesional surgery was previously performed elsewhere. In 27 patients primarily treated at Rizzoli with unifocal localization, surgery was used in 15 cases, surgery and radiotherapy in 7, surgery with radio/chemotherapy in 1 and no surgery in 4 (2 radiotherapy, 1 radio/chemotherapy and 1 embolization). Eight unifocal patients already treated elsewhere had surgery in 3 cases, surgery and radiotherapy in 3, surgery with radio/chemotherapy in 1 and surgery plus chemotherapy in 1. Three of the unifocal cases had further bone involvement subsequently. Nine multifocal patients primarily treated at Rizzoli had surgery in 4 cases, surgery and radiotherapy in 4, surgery with radio/chemotherapy in 1. The 2 previously treated multifocal HE had 1 surgery and 1 radiotherapy. Six patients died: 3 of disease, 1 of radio-induced osteosarcoma, 2 of different disease. Two patients are AWD. Of remaining 40 patients, 26 are NED (mean follow up 9 years), 11 NED after treatment of recurrence, 1 NED after treatment of radio-induced sarcoma. No lung metastases were diagnosed after treatment. All 10 cases previously treated intralesionally had recurrence. Two of 15 unifocal cases treated with surgery recurred (13%). None of 9 resected unifocal cases previously untreated recurred. Two of 21 pts. with radiotherapy (9.5%) had radio-induced sarcoma. Surgery is recommended, resection when feasible. Radiotherapy, implying risk of induced sarcoma, should be reserved to multifocal or unresectable cases. Adverse prognostic factor was previous intralesional surgery.
Osteosarcoma is the most common second malignancy seen in retinoblastoma survivors. Risk of developing osteosarcoma in this group is estimated approximately 500 times higher than the general population. Prognosis in this setting has been reported significantly worse than conventional osteosarcoma despite multimodal management. Purpose of this study was to evaluate clinical features, molecular aspects and outcome of treatment in this subgroup of osteosarcoma patients. Between 1985 and 2004, from a total of about 1100 osteosarcomas, 7 survivors of retinoblastoma developing high-grade osteosarcoma as second malignancy presented at the authors’ Institution. Retrospective study was undertaken to analyze presentation, tissue expression of RB1, P53, PGP and DHFR, treatment and outcome of both retinoblastoma and osteosarcoma. Retinoblastoma was bilateral in 5 cases and unilateral in two. All the patients had been treated with a combination of surgery +/− chemotherapy +/− radiation. None of them had evidence of retinoblastoma at the time of second malignancy diagnosis. Average age at diagnosis of osteosarcoma was 14 years (9–17 years), mean interval between the two malignancies was 155 months. All the osteosarcomas were in the appendicular skeleton, all but one around the knee. Molecular analysis showed defective RB1 gene in all cases All the seven patients received contemporary multimodal management for osteosarcoma. All but one patient died of osteosarcoma within 30 months from diagnosis. The living patient had local recurrence 9 years after limb salvage and is currently disease free following amputation. Prognosis of osteosarcoma in retinoblastoma patients remains poor as compared to conventional high grade osteosarcoma despite multimodal management. No obvious correlation was found between poor prognosis and P53, PGP and DHFR expression.